



BIOEUROPE PRESENTATION – SEEKING OPPORTUNITIES IN ONCOLOGY

F. R. Martelet, M.D., CEO

26 – 29 October 2020

Forward-looking statement

IMPORTANT NOTICE

The information in this presentation shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities referred to herein in any jurisdiction in which such offer, solicitation or sale would require preparation of further prospectuses or other offer documentation, or be unlawful prior to registration, exemption from registration or qualification under the securities laws of any such jurisdiction.

No representation or warranty expressed or implied is made as to, and no reliance should be placed on the fairness, accuracy, completeness or correctness of the information or opinion contained herein.

The information in this presentation may not be forwarded or distributed to any other person and may not be reproduced in any manner whatsoever. Any forwarding, distribution, reproduction, or disclosure of this information in whole or in part is unauthorized. Failure to comply with this directive may result in a violation of the Securities Act or the applicable laws of other jurisdictions.

FORWARD LOOKING STATEMENTS

This presentation contains forward-looking statements that reflect management's current views with respect to certain future events and potential financial performance. Although Oasmia believes that the expectations reflected in such forward-looking statements are reasonable, no assurance can be given that such expectations will prove to have been correct. Accordingly, results could differ materially from those set out in the forward-looking statements as a result of various factors.

Important factors that may cause such a difference for Oasmia include but are not limited to: (i) the macroeconomic development, (ii) change in the competitive climate and (iii) change in interest rate level.

This presentation does not imply that Oasmia has undertaken to revise these forward-looking statements, beyond what is required by applicable law or applicable stock exchange regulations if and when circumstances arise that will lead to changes compared to the date when these statements were provided.


Oasmia – an innovation-focused specialty pharmaceutical company




Founded in **1999**
Based in Uppsala, Sweden



XR-17™ technology platform
Enhances the intravenous delivery of established and novel drugs in diseases including cancer



A growing pipeline, focused on **Oncology** and with potential in other therapeutic areas



NASDAQ Stockholm **2010**
Market Cap approx. SEK 2.0 B



R&D-focused Production
Facility in Uppsala, Sweden



New Leadership
since March 2020

The new team leading Oasmia's transformation



FRANCOIS MARTELET, M.D., Master's Degree Business
Chief Executive Officer

Previous experience:
CEO in Biotechnology/ BioPharma in UK, Denmark, US and senior executive global roles at Novartis Oncology, Merck & Co., Inc with large P&L responsibility

FREDRIK JÄRRSTEN*
Chief Finance Officer

ELIN TRAMPE,
Chief Technical Officer

REINHARD KOENIG, M.D.
Acting Chief Medical Officer

PETER SELIN*
Chief Business Officer



ANDERS HÄRFSTRAND, M.D., PhD.
Non-executive Chairman

Previous experience: Pharma BoD, M&A, former executive positions in Pfizer, Pharmacia, Pharmacia & Upjohn

HEGE HELLSTRÖM,
B.A.
Board Member

BIRGIT STATTIN NORINDER, MSc.
Board Member

PETER ZONABEND,
LL.M, EMLE
Board Member



Meeting the challenges of poor drug solubility

POOR API¹ SOLUBILITY

Major challenge in
drug development

Critical to drug
bioavailability

c.40% OF APPROVED DRUGS AFFECTED²

70-90% of pipeline
drugs classed as
poorly soluble²

Leading cause of
project
termination

A FACTOR IN SERIOUS ADVERSE EVENTS (SAEs)

Solubility enhancers
can cause SAEs and/
or require use of
further drugs

An accepted trade
off in cancer
therapy

\$180 bn
SPENT ON
PHARMA R&D
EVERY YEAR³


69%
OF DRUGS
FAIL DUE TO
LOW
SOLUBILITY³

1) API = Active Pharmaceutical Ingredient - the ingredient in a pharmaceutical drug that is biologically active
2) Nikolakakis & Partheniadis
3) GlobalData



XR-17™ powerful platform that can increase solubility of insoluble compounds

Active Pharmaceutical Ingredient
(API)



WATER INSOLUBLE




XR-17™



Hydrophilic head
Hydrophobic chain



XR-17™ + API




WATER SOLUBLE

XR-17™ increases small molecule solubility and potentially improves safety and efficacy of new formulations



XR-17™ – the solution to your water solubility issues





XR-17™ – platform validated by success of Apealea® in oncology



Drug load capacity, enabling high drug delivery capability



Shorter infusion time^{1,2}



Superior solubility compared with other platforms and technologies, enhances bioavailability of API



Strong, validated safety in cancer indication¹




No mandatory or limited need for steroid pre-medication¹



Free from alcohol, Cremophor EL, Polysorbate-80 and Human albumin, which can cause numerous side effects

Building a diverse portfolio based on XR-17™ platform technology



Product	Indication	Pre-clinical	Phase I	Phase II	Phase III	Registration / approval	Geography	
Human Health Portfolio								
Apealea® / Paclical® (paclitaxel)	Ovarian cancer	▶				Pre-NDA meeting	USA	
	Ovarian cancer	▶ ✓					EU / EEA	
Docetaxel micellar	Prostate cancer	▶					Global	
New API	Undisclosed	▶						Global
XR-19 (combination)	Assessments in various cancers	▶						Global
Animal Health Portfolio (Canines)								
Paccal vet (paclitaxel)	Mammary Carcinoma	▶						USA
Doxophos vet (doxorubicin)	Lymphoma	▶						USA





Apealea[®] – offering an improved treatment option



Approved in EU/EEA for treatment of first relapse ovarian cancer¹ and in Russia for first line and relapsed ovarian cancer²

Current standard of care in Ovarian cancer is carboplatin + paclitaxel

A subset of patients cannot tolerate solvent-based paclitaxel

Apealea[®] is a solvent-free IV formulation of paclitaxel using XR-17[™]

- *Free from polyoxyethylated castor oil and dehydrated alcohol*
- *No need for mandatory glucocorticosteroids pre-medication*
- *Shorter infusion and overall 'chair' time*



1) Apealea[®] Summary of Product Characteristics. www.ema.europa.eu

2) Paclical[®] Instructions for medical use. <https://grls.rosminzdrav.ru>



Apealea[®] – global partnership worth up to \$698m + royalties



Agreement with US-based Elevar Therapeutics, subsidiary of South Korea's HLB



\$20_M

Upfront payment

%

Double digit royalties on global Apealea[®] sales

\$678M


Milestones based on regulatory and sales achievements




Oasmia retains sole control over development of XR-17[™] in other APIs



Named patient program initiated with Tanner Pharma Group ex US
Elevar recently announced a commercialization agreement with Taiba for MENA markets;
negotiations with partners for other key markets advancing well



Oasmia's business model



Model successfully applied to Apealea[®], out-licensed globally to Elevar Therapeutics



In-licensing opportunities mainly in oncology



- Oasmia is also open to collaborations to support partners' R&D and overcome solubility challenges

Arrange a meeting with us via the BioEurope partnering system to find out more.....



Out-licensing opportunities in animal health portfolio

Paccal Vet

- A new XR-17™-based formulation of paclitaxel in development for the treatment of mastocytoma in dogs
 - Identical to Apealea® / Paclical (for human use)

Doxophos Vet

- A patented formulation of doxorubicin in combination with XR-17™
- In development for the treatment of lymphoma, one of the most common forms of cancer in dogs
- Results from Phase I and Phase II studies will form part of the application to the FDA for conditional approval

Arrange a meeting with us via in the BioEurope partnering system to find out more.....

Building a sustainable, profitable specialty pharma company



APEALEA® APPROVED IN EUROPE



Lead product
launched for
advanced ovarian
cancer

Opportunity to
develop in several
other cancer
indications

A GLOBAL PARTNERSHIP



Elever Apealea® deal
worth up to \$678
million plus royalties

Elever evaluating
European and Asian
commercial partners

A GROWING ONCOLOGY PIPELINE



Underpinned by
strong IP protection

Docetaxel micellar
poised for the clinic

XR-19 and a new API
in preclinical
development

WELL POSITIONED FOR PARTNERING / M&A



Proven development,
regulatory and BD
skills

Lean flexible
structure with low
cash burn and solid
cash position

Contact us for more information



Find out more about our partnering opportunities by emailing our partnering team at:

partners@oasmia.com